Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine SR in Major Depressive Disorder
NCT00887224Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Desvenlafaxine succinate sustained release 50 mg with Placebo (2 arms). Primary endpoint: Time to Relapse Following Randomization to the Double-blind Phase at 26 weeks. Started Jun 2009; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00887224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887224.